GlaxoSmithKline (GSK) in July made its consumer health products division a separate entity as it transforms into a world-leading biopharmaceutical company. By uniting science, technology and talent, the company is aiming to prevent and treat diseases with innovative vaccines, specialty pharmaceuticals and general medicines.
GSK’s headquarters annually invests NT$192 billion (US$6.07 billion) in research and development, focusing on immune science and advanced technologies in human genetics. GSK’s drug and vaccine development focuses on infectious diseases, HIV, oncology and immunology.
Investing in clinical trial research each year, GSK also brings drug development to Taiwan. It cooperates with 17 medical institutes and research centers in Taiwan to help domestic medical research keep pace with international trends and enhance Taiwan’s status as a center for clinical research in the Asia-Pacific region.
Photo courtesy of GSK Taiwan
GSK has launched a revamped brand identity system, which was modified from its former orange logo consisting of lowercase “gsk” and a beating heart. The new logo adopts gradient orange, capitalized “GSK,” and digital and technological lines. Its design brings out a striking, eye-catching image, while conveying GSK’s goals and ideas for the future.
The arrow in the new logo symbolizes GSK’s combination of digital, social and environmental concerns as a “signal to move ahead together” in the biopharmaceutical industry. The curve in the logo symbolizes the ability of the immune system to adapt to and evolve along with the environment.
GSK’s Taiwan branch was established 43 years ago, and has since protected the health of Taiwanese.
“After transforming the organization, our new ambitions and new purpose is to expand our impact here in Taiwan by protecting and treating more patients, to make GSK a place where people can thrive, where they can succeed, grow and be happy at work, all underpinned by doing everything with integrity and care,” GSK Taiwan vice president and general manager Mick Stanley said.
The newly transformed GSK is focusing on protecting the health of Taiwanese with pharmaceuticals and vaccines, advocating and practicing the values of diversity and inclusion, and caring for employees and practicing sustainable development, all of which form the company’s business philosophy.
Being “ambitious for patients” is part of the corporate culture, which GSK attaches great importance to.
“In addition to ‘ambitious for patients,’ GSK’s culture also emphasizes ‘accountable for impact.’ We hope to expand our impacts on Taiwanese people,” Stanley said. “We hope we can move ahead together to defeat disease with medicines and vaccines.”
GSK provides as many as 50 kinds of prescription medicines and more than 15 kinds of vaccines, for children and adults, and endeavors to do its utmost for the health of Taiwanese.
Every day, 2 million doses of vaccines produced by GSK are administered around the world. In the past few years, GSK has advocated for adult vaccination. For example, GSK Taiwan has recently launched a new vaccine against the herpes zoster virus to protect against shingles.
To help Taiwanese become aware of the necessity of adult vaccination, GSK is working with entities in Taiwan to create and promote comprehensive information and an environment for adult vaccination.
GSK provides vaccines for infectious diseases that could occur at every stage of life. It helps provide proper immune protection against meningitis, quadrivalent influenza, polio, measles and other diseases. In Taiwan, an average of 40 percent of children receive vaccines provided by GSK.
GSK is also concerned about the healthcare challenges faced by Taiwan’s rapidly aging population. Accordingly, GSK has been discussing important policy developments with the government through the American Chamber of Commerce in Taiwan, the European Chamber of Commerce Taiwan and the International Research-Based Pharmaceutical Manufacturers Association, with the aim of helping Taiwan lay a solid foundation for its medical environment in the decades to come.
Additionally, since the invention of the first-ever medicine for the treatment of HIV, GSK has continuously worked to improve the health and quality of life of people living with HIV, and has cooperated with government entities and patient groups.
In addition to vaccines, GSK also leads the industry in the treatment and prevention of diseases such as respiratory illnesses. For people with asthma, chronic obstructive pulmonary disease and other respiratory diseases who need drugs for treatment, GSK helps them with a variety of inhaled medicines.
The world’s first inhaler was developed by GSK.
The company helps more than 2 million people with respiratory diseases every year in Taiwan, and allows them to breathe freely with improved quality of life.
TECH CLUSTER: The US company’s new office is in the Shalun Smart Green Energy Science City, a new AI industry base and cybersecurity hub in southern Taiwan US chip designer Advanced Micro Devices Inc (AMD) yesterday launched an office in Tainan’s Gueiren District (歸仁), marking a significant milestone in the development of southern Taiwan’s artificial intelligence (AI) industry, the Tainan City Government said in a statement. AMD Taiwan general manager Vincent Chern (陳民皓) presided over the opening ceremony for the company’s new office at the Shalun Smart Green Energy Science City (沙崙智慧綠能科學城), a new AI industry base and cybersecurity hub in southern Taiwan. Facilities in the new office include an information processing center, and a research and development (R&D) center, the Tainan Economic Development Bureau said. The Ministry
ADVERSARIES: The new list includes 11 entities in China and one in Taiwan, which is a local branch of Chinese cloud computing firm Inspur Group The US added dozens of entities to a trade blacklist on Tuesday, the US Department of Commerce said, in part to disrupt Beijing’s artificial intelligence (AI) and advanced computing capabilities. The action affects 80 entities from countries including China, the United Arab Emirates and Iran, with the commerce department citing their “activities contrary to US national security and foreign policy.” Those added to the “entity list” are restricted from obtaining US items and technologies without government authorization. “We will not allow adversaries to exploit American technology to bolster their own militaries and threaten American lives,” US Secretary of Commerce Howard Lutnick said. The entities
Minister of Finance Chuang Tsui-yun (莊翠雲) yesterday told lawmakers that she “would not speculate,” but a “response plan” has been prepared in case Taiwan is targeted by US President Donald Trump’s reciprocal tariffs, which are to be announced on Wednesday next week. The Trump administration, including US Secretary of the Treasury Scott Bessent, has said that much of the proposed reciprocal tariffs would focus on the 15 countries that have the highest trade surpluses with the US. Bessent has referred to those countries as the “dirty 15,” but has not named them. Last year, Taiwan’s US$73.9 billion trade surplus with the US
The Taipei International Cycle Show (Taipei Cycle) yesterday opened at the Taipei Nangang Exhibition Center, with the event’s organizer expecting a steady recovery in the industry this year following a tough last year. This year, 980 companies from 35 countries are participating in the annual bicycle trade show, showcasing technological breakthroughs and market development trends of the bicycle industry at 3,600 booths, the Taiwan External Trade Development Council (TAITRA, 外貿協會) said in a statement. Under the theme “Ride the Revolution,” the exhibition has attracted more than 3,500 international buyers from 80 countries to preregister for the four-day event, which is expected to
RSS